Literature DB >> 28062134

Vascular expansion during worsening of heart failure: Effects on clinical features and its determinants.

Hajime Kataoka1.   

Abstract

BACKGROUND: This study investigated the relation of the changes in serum solutes/albumin to the level of vascular expansion and clinical features during worsening HF.
METHODS: Data from 47 patients with acute on chronic HF worsening were analyzed. Blood tests included hemoglobin, hematocrit, albumin, solutes (Na/K/Cl/BUN/Cr), and b-type natriuretic peptide (BNP). The relative change in the vascular expansion from stable to worsening HF was estimated based on changes in the plasma volume (%PV).
RESULTS: When divided into two groups based on the median %PV, the clinical features of the expansion group (11≤%PV [range 11% to 36%]; n=24) included a lower incidence of crackles (13% vs. 52%, p=0.005) and a tendency toward preserved renal function (83% vs. 57%, p=0.06) compared with the non-expansion group (%PV [range -19% to 11%]<11; n=23), whereas the increase in body weight and log BNP did not differ between groups. The expansion group had a greater increase in serum Na (3.58±4.43 vs. -0.11±3.31mEq/L, p=0.0016) and Cl (5.54±6.24 vs. -0.03±4.18mEq/L, p=0.0006), and a decrease in serum albumin (-0.37±0.3 vs. -0.16±0.3g/dL, p=0.04) and creatinine (-0.28±0.39 vs. -0.06±0.22mg/dL, p=0.027) from stability to worsening HF. Multivariate logistic regression analysis revealed an independent association between the increase in %PV and the increase in the serum Cl concentration from stability to worsening HF (odds ratio: 12.2, 95% confidence interval: 1.78-83.8, p=0.011).
CONCLUSIONS: Though this study is observational and does not allow for causal inference, it may nonetheless be speculated that a greater accumulation of Cl in the blood vessels acts to increase or maintain intravascular volume, which induces different clinical features of HF.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Body fluid; Chloride; Heart failure; Pathophysiology; Vascular volume

Mesh:

Substances:

Year:  2016        PMID: 28062134     DOI: 10.1016/j.ijcard.2016.12.059

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Acetazolamide as a potent chloride-regaining diuretic: short- and long-term effects, and its pharmacologic role under the 'chloride theory' for heart failure pathophysiology.

Authors:  Hajime Kataoka
Journal:  Heart Vessels       Date:  2019-05-21       Impact factor: 2.037

Review 2.  Estimated plasma volume status in heart failure: clinical implications and future directions.

Authors:  Masatake Kobayashi; Nicolas Girerd; Kevin Duarte; Tahar Chouihed; Taishiro Chikamori; Bertram Pitt; Faiez Zannad; Patrick Rossignol
Journal:  Clin Res Cardiol       Date:  2021-01-06       Impact factor: 5.460

3.  Mechanistic insights into chloride-related heart failure progression according to the plasma volume status.

Authors:  Hajime Kataoka
Journal:  ESC Heart Fail       Date:  2022-04-06

4.  Dynamic changes in serum chloride concentrations during worsening of heart failure and its recovery following conventional diuretic therapy: A single-center study.

Authors:  Hajime Kataoka
Journal:  Health Sci Rep       Date:  2018-10-02

5.  Vasopressin antagonist-like effect of acetazolamide in a heart failure patient: a case report.

Authors:  Hajime Kataoka
Journal:  Eur Heart J Case Rep       Date:  2018-07-02

6.  Proposal for heart failure progression based on the 'chloride theory': worsening heart failure with increased vs. non-increased serum chloride concentration.

Authors:  Hajime Kataoka
Journal:  ESC Heart Fail       Date:  2017-07-17

7.  Enhancement of the serum chloride concentration by administration of sodium-glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patients: a pilot study.

Authors:  Hajime Kataoka; Yuichi Yoshida
Journal:  Diabetol Metab Syndr       Date:  2020-01-13       Impact factor: 3.320

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.